Work Here?
Work Here?
Work Here?
Industries
AI & Machine Learning
Biotechnology
Company Size
51-200
Company Stage
Series B
Total Funding
$272.5M
Headquarters
Burlingame, California
Founded
2019
Genesis Therapeutics focuses on developing new medicines by using artificial intelligence in the drug discovery process. The company employs a method that combines 3D spatial graph modeling and advanced molecular simulation to identify potential drug candidates. This approach enables them to explore new chemical spaces and discover novel protein targets, which can lead to important new medicines. Unlike many competitors, Genesis Therapeutics operates on a business-to-business model, partnering with other biotech and pharmaceutical companies, such as Eli Lilly, to provide their AI-driven drug discovery services. Their goal is to accelerate the development of new drugs through strategic partnerships and successful collaborations.
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$272.5M
Above
Industry Average
Funded Over
3 Rounds
Industry standards
Competitive salary
Equity
Medical, dental, & vision insurance
401(k) program
Nvidia’s venture arm, NVentures, has increased its investment in AI drug discovery firm Genesis Therapeutics. Genesis, founded by Evan Feinberg, has raised over $300 million, including a $200 million Series B in 2023. The collaboration aims to enhance Genesis' AI platform, GEMS, for drug discovery. Genesis is also working with Gilead, Eli Lilly, and Genentech on various projects. The company plans to expand its workforce beyond its current 80 employees.
Genesis Therapeutics receives equity investment from NVIDIA.
Genesis Therapeutics has partnered with NVIDIA to enhance its AI platform, GEMS, for drug discovery. This collaboration is supported by additional funding from NVentures, NVIDIA's venture capital arm, following its participation in Genesis' $200 million Series B financing in August 2023. The partnership aims to optimize computational methods like equivariant neural networks to analyze complex 3D molecular structures, targeting diseases with high unmet needs and previously undruggable targets.
Gilead Sciences (GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.
Gilead and Genesis Therapeutics announce strategic collaboration to discover and develop novel therapies.
Find jobs on Simplify and start your career today
Industries
AI & Machine Learning
Biotechnology
Company Size
51-200
Company Stage
Series B
Total Funding
$272.5M
Headquarters
Burlingame, California
Founded
2019
Find jobs on Simplify and start your career today